Anaemia and iron deficiency in children with inflammatory bowel disease

Size: px
Start display at page:

Download "Anaemia and iron deficiency in children with inflammatory bowel disease"

Transcription

1 Journal of Crohn's and Colitis (2012) 6, Available online at Anaemia and iron deficiency in children with inflammatory bowel disease Anthony E. Wiskin a, Ben J. Fleming b, Stephen A. Wootton a, R. Mark Beattie c, a NIHR Biomedical Research Unit (Nutrition, Diet & Lifestyle), Southampton General Hospital, SO16 6YD, UK b School of Medicine, University of Southampton, Southampton General Hospital, SO16 6YD, UK c Paediatric Medical Unit, Southampton General Hospital, SO16 6YD, UK Received 19 September 2011; received in revised form 2 December 2011; accepted 2 December 2011 KEYWORDS Inflammatory bowel disease; Anaemia; Iron deficiency; Paediatrics Abstract Background and aims: Anaemia and iron deficiency are common in children with Inflammatory Bowel Disease (IBD) however it is not known if the prevalence of anaemia and iron deficiency alters following diagnosis. Methods: Laboratory results from diagnosis, and at follow up one and two years later were recorded retrospectively in children with IBD recruited from a tertiary centre. Anaemia was defined using WHO standards and iron deficiency defined using published guidelines. Results: 46 children (16 girls) with Crohn's disease and 34 children (18 girls) with UC were studied. 75% of children with IBD were anaemic at diagnosis, 30% were anaemic at follow up two years later. 90% of children with Crohn's and 95% of children with Ulcerative Colitis (UC) were iron deficient at diagnosis. At follow up two years later 70% of children with Crohn's and 65% of children with UC were iron deficient. Conclusions: Persistent anaemia and iron deficiency are common in childhood IBD, prevalence alters with duration of time from diagnosis Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation. 1. Background These data have been accepted for presentation at the British Association of Parenteral and Enteral Nutrition conference in Harogate, UK in November Corresponding author at: Paediatric Medical Unit, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK. Tel.: ; fax: address: mark.beattie@suht.swest.nhs.uk (R.M. Beattie). 25% of inflammatory bowel disease (IBD) presents in childhood. Anaemia is common and studies of children with IBD report prevalence between 41% and 75%. 1 5 The aetiology of anaemia is multi-factorial. Investigation often reveals a combination of iron deficiency and the anaemia of chronic disease but anaemia may be induced by other /$ - see front matter 2011 Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation. doi: /j.crohns

2 688 A.E. Wiskin et al. Table 1 WHO definition of anaemia in childhood. Age (years) Haemoglobin (g/l) b Non-pregnant girls N Boys N nutrient deficiencies, or as a result of drugs used to treat the primary disease. The broad prevalence range in paediatric studies reflects the different methods used to define anaemia including various cut-offs for haematocrit and haemoglobin values and potentially the duration and severity of disease in the children studied. The clinical significance of anaemia in children with IBD and the extent to which correcting anaemia is associated with improvements in disease activity or growth has not been determined. However, in adult studies improvements in quality of life, independent of disease activity, have been attributed to improvements in haemoglobin concentration. 6 We can only assume that this is also true in children and adolescents. If anaemia is not being adequately treated in children with IBD then its detection and subsequent treatment may lead to strategies to improve quality of life. Revel Vilk and Goodhand suggest iron deficiency is responsible for 40% 4 and 88% 5 of the cases of anaemia in children with IBD. However data is scarce on the prevalence of iron deficiency per se. Serum ferritin, transferrin and percentage transferrin saturation are commonly used to determine iron deficiency as bone marrow biopsy to determine the amount of stainable iron in the bone marrow cannot be widely performed. However, the interpretation of iron indices in children with disease requires adequate consideration of inflammation. Serum ferritin is a positive acute phase reactant and increases with inflammation which may mask underlying functional iron deficiency. In the context of IBD interpreting serum ferritin relative to the C reactive protein has been proposed as a method of detecting iron deficiency in patients with IBD. 7 The aim of this study was to establish the prevalence of anaemia and of iron deficiency at diagnosis and while under follow up from children attending a regional paediatric gastroenterology service. 2. Methods This was a retrospective cohort study and data were gathered from electronic records. Children diagnosed following the Porto criteria 8 with disease extent recorded following Paris classification 9 were recruited from the regional service to studies examining nutritional status in IBD 10,11 approved by the local research ethics committee. The management of children with IBD in our centre follows published guidelines, 12 the aims of treatment are to control disease activity and optimise growth. No specific guideline is followed for the investigation and treatment of children with IBD who are anaemic or iron deficient. Blood results from diagnosis, and at follow up one and two years later were recorded where available. Children with haemoglobinopathies and those who had received blood transfusions were excluded. Anaemia was defined using cutoffs for haemoglobin concentration specific to age groups and gender in accordance with WHO standards (Table 1). Iron deficiency was identified using two approaches, firstly; a transferrin saturation of b16% and secondly; a serum ferritin of b30 μg/l (for children with a CRP b10 mg/l) or b100 μg/l (for children with a CRP 10 mg/l). 7 These criteria for iron deficiency were chosen as they are specific to this patient group and attempt to correct for the role of ferritin as an acute phase reactant. Data are quoted as median (25th, 75th centile). Statistical analysis was performed using SPSS 18.0 (SPPS Inc. Illinois). 3. Results 3.1. Crohn's disease 46 children (16 girls) with Crohn's disease were studied. Median age of 12, range 4 to 16 years. 11 children had colonic disease, 32 had ileo-colonic disease. Upper GI disease was Ulcerative Colitis Crohn s disease At diagnosis One year Two years Figure 1 Haemoglobin concentration of children with IBD grouped by disease type at time of diagnosis, and at follow up one and two years later.

3 Anaemia and iron deficiency in childhood IBD 689 Table 2 Prevalence of anaemia and iron deficiency in children with Crohn's disease grouped by C reactive protein. CRPb10 CRP 10 CRPb10 CRP 10 CRPb10 CRP 10 Anaemia 5/8 (63%) 26/35 (74%) 11/20 (55%) 7/10 (70%) 4/20 (20%) 4/6 (67%) Iron deficient (transferrin saturation) 4/4 (100%) 20/22 (91%) 14/25 (56%) 8/9 (89%) 9/15 (60%) 4/4 (100%) Iron deficient (ferritin corrected for CRP) 6/7 (86%) 22/25 (88%) 23/28 (82%) 9/9 (100%) 13/16 (81%) 2/3 (67%) present in 18 children including two who had isolated upper GI disease. One child had perianal disease only. 37 children received thiopurines, 30 received aminosalicylates and 4 received biological agents. Median haemoglobin at diagnosis was 111 (99, 119) g/l and rose to 122 (116, 131) g/l at one year and 127 (121,131) at two years (Fig. 1). Median C reactive protein at diagnosis was 22 (12, 43) mg/l, at one year was 7(1, 9) mg/l and fell to 3 (1, 10) mg/l at two years. Median transferrin saturation and median ferritin at diagnosis were 6 (4, 9)% and 25 (15, 54) μg/l; at one year were 14 (8, 16)% 16 (9, 29) μg/l; and at two years were 13 (8, 25)% and 22 (17, 29) μg/l respectively. Prevalence of anaemia and iron deficiency at diagnosis, one year and two years is shown in Table 2. It has been suggested that the prevalence of anaemia may be directly related to the degree of untreated intestinal inflammation which may be reflected by treatment type as immunomodulators achieve better mucosal remission. Data showing the prevalence of anaemia in patients grouped by treatment type is shown in Table Ulcerative colitis 34 children (18 girls) with UC were studied. Median age of 11, range 10 to 16 years. 13 children had left sided disease, one child had proctitis and 20 children had pancolitis. During the two years evaluated, 30 children received aminosalicylates and 15 received thiopurines. No children received biological agents. Median haemoglobin at diagnosis was 110 (94, 122) g/l and rose to 124 (110, 127) g/l at one year and 123 (114, 139) at two years (Fig. 1). Median C reactive protein at diagnosis was 2 (1, 5) mg/l, at one year was 1 (1, 3) mg/l, and at 2 years was 1 (1, 2) mg/l. Median transferrin saturation and median ferritin at diagnosis were 8 (4, 17)% and 8 (5, 21) μg/l; at one year were 13 (8, 32)% and 12 (6, 24) μg/l; and at two years were 23 (19, 32)% and 20 (11, 35) μg/l. Prevalence of anaemia and iron deficiency at diagnosis, one year and two years is shown in Table 4. Data Table 3 Prevalence of anaemia in children with Crohn's grouped by treatment received. Aminosalicylate alone 7/8 (88%) 3/7 (43%) 0/2 Thiopurine alone 11/15 (73%) 5/14 (36%) 1/7 (14%) Aminosalicylate and 12/18 (67%) 7/18 (39%) 5/13 (39%) thiopurine showing the prevalence of anaemia in patients grouped by treatment type is shown in Table 5. Combining data from both disease groups there was poor agreement between the two methods in the classification of children as iron deficient (kappa 0.2 standard error 0.08, pb0.01). 4. Discussion Anaemia is common in this cohort of children with IBD with a prevalence of 74% at presentation, falling to 42% at one year, and 32% at two years and is similar between those with Crohn's or Ulcerative Colitis. Improvement in prevalence of anaemia occurs relative to decreased median CRP which raises two possibilities. Firstly, that haemoglobin concentration reflects disease activity and underlying inflammation and secondly that both of these parameters may reflect underlying nutritional status. It has been suggested that treatment given may be a proxy for underlying inflammation since immunomodulators produce better mucosal healing. However there may be a confounding effect as patients with mild disease are not given thiopurines and only those with most severe disease are given biologics. The degree of mucosal healing achieved in mild disease with less aggressive treatment is not known. In this study treatment given does not appear to relate to the prevalence of anaemia in Crohn's or Ulcerative Colitis although small numbers of children studied precludes detailed analysis. Whatever the cause the prevalence of anaemia at two years after diagnosis suggests persistent anaemia is common. In this cohort iron deficiency is more common than anaemia. Two years after diagnosis between 70% and 80% of children with Crohn's disease are iron deficient. There are several potential mechanisms for iron deficiency including decreased oral intake, increased loss from inflamed GI mucosa, impaired absorption, and altered metabolism as part of the inflammatory response. Some of these effects may be mediated by hepcidin. Hepcidin is a peptide involved in iron homeostasis. Following signalling from pro-inflammatory cytokines hepcidin production is upregulated in the liver. Hepcidin decreases the activity of ferroportin preventing the transport of iron out of the enterocyte, and thereby promoting excretion from the body. 13 Clinicians require suitable investigations to define iron deficiency in order to determine which patients may benefit from iron therapy. A recent review in this journal examined the role of markers to differentiate iron deficiency anaemia from anaemia of chronic disease. The authors suggest that iron regulators such as hepcidin and classic erythrocyte parameters are not useful. 14 The two criteria proposed by Gasche 7 have been used in this study although it is not entirely

4 690 A.E. Wiskin et al. Table 4 Prevalence of anaemia and iron deficiency in children with Ulcerative Colitis grouped by C reactive protein. CRPb10 CRP 10 CRPb10 CRP 10 CRPb10 CRP 10 Anaemia 21/29 (72%) 2/2 (100) 10/27 (37%) 1/3 (33%) 5/19 (26%) 1/2 (50%) Iron deficient (transferrin saturation) 13/17 (76%) 0/0 (0%) 13/23 (57%) 1/3 (33%) 3/17 (18%) 0/1 (0%) Iron deficient (ferritin corrected for CRP) 18/19 (95%) 1/1 (100%) 19/24 (79%) 3/3 (100%) 11/16 (69%) 0/1 (0%) clear how well these parameters reflect functional iron deficiency. It is clear from this study that the agreement between the two methods proposed by Gasche is poor. The ratio of transferrin receptors to log ferritin (TfR-F Index) is an outstanding parameter for identifying patients with depleted iron stores, determined by stainable iron in bone marrow 15 and has recently been evaluated in patients with IBD. 16 The use of this parameter in further studies may be appropriate to determine improvements in iron status in response to treatment of underlying inflammation, improvements in nutritional status and iron supplementation. Treatment of iron deficiency in IBD is not straightforward. In this study nine children with Crohn's and four with Ulcerative Colitis received an iron supplement at some stage during the study interval. However the prescription of these supplements was not consistent and this study was unable to observe their efficacy. It is proposed that oral iron supplementation may generate radical oxygen species, provoke inflammation, and thereby exacerbate gastro-intestinal symptoms 17 leading to intolerance. However there is also evidence to the contrary from a prospective trial of adults with IBD. 18 Intra-venous iron preparations avoid the problem of gastro-intestinal side effects and appear efficacious in adult studies. 19 There are few studies which report the use of intra-venous iron in children. One retrospective study suggests the use of intra-venous iron in children with IBD is safe. 20 Another has demonstrated that intra-venous iron may be of benefit in children who have not responded to therapy with oral iron. 21 However data on the tolerability and efficacy of iron supplementation (oral and intra-venous) in children with IBD is scarce. The authors recognise that the retrospective nature of this study may introduce bias as children with the most apparent deficit are those most likely to have bloods requested. While this may be the case it is notable that the prevalence of anaemia in this study is comparable to previous work. This study suggests that iron deficiency and anaemia are significant on-going issues in the care of children with IBD and highlights the scale of the problem even in children under follow up. Reliable diagnostic criteria are needed to help identify children who may be suitable for therapeutic intervention which in turn may make significant improvements in quality of life. Table 5 Prevalence of anaemia in children with Ulcerative Colitis grouped by treatment received. Aminosalicylate 12/17 (71%) 5/16 (31%) 1/9 (11%) Aminosalicylate and thiopurine 10/13 (77%) 5/13 (39%) 4/10 (40%) Conflict of interest The authors have no conflicts of interest to declare. Acknowledegments This project received no specific funding. AEW is funded by the NIHR Biomedical Research Unit (Nutrition, Diet & Lifestyle) Southampton. AEW conceived of the study, assisted in data collection and analysis and drafted the manuscript. BJF completed data collection and analysis and assisted in drafting the manuscript. SAW assisted with data analysis and reviewed final manuscript. RMB conceived of the study, assisted with data analysis and reviewed final manuscript. References 1. Burbige EJ, Huang SH, Bayless TM. Clinical manifestations of Crohn's disease in children and adolescents. Pediatrics 1975;55: Beeken WL. Absorptive defects in young people with regional enteritis. Pediatrics 1973;52: Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis. Course, and treatment. Gastroenterology 1977;73: Revel-Vilk S, Tamary H, Broide E, Zoldan M, Dinari G, Zahavi I, et al. Serum transferrin receptor in children and adolescents with inflammatory bowel disease. Eur J Pediatr 2000;159: Goodhand JR, Kamperidis N, Rao A, Laskaratos F, McDermott A, Wahed M, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis 2011 May 20. doi: /ibd [Epub ahead of print]. 6. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006;12: Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13: Inflammatory bowel disease in children and adolescents: recommendations for diagnosis the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41: Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011 Jun;17(6): Wiskin AE, Wootton SA, Culliford DJ, Afzal NA, Jackson AA, Beattie RM. Impact of disease activity on resting energy

5 Anaemia and iron deficiency in childhood IBD 691 expenditure in children with inflammatory bowel disease. Clin Nutr 2009;28: Wiskin AE, Wootton SA, Cornelius VR, Afzal NA, Elia M, Beattie RM. No relationship between disease activity measured by clinical score, local and systemic inflammatory markers and resting energy expenditure in childhood Crohn's disease. J Pediatr Gastroenterol Nutr currently available on-line. First available 2011 Sep 14 doi: /mpg.0b013e318236b19a. 12. BSPGHAN Guidelines for the Management of Inflammatory Bowel Disease in Children in the United Kingdom. British Society of Paediatric Gastroenterology Hepatology and Nutrition; Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. JClinInvest 2004;113: Oustamanolakis P, Koutroubakis IE, Kouroumalis EA. Diagnosing anemia in inflammatory bowel disease: beyond the established markers. J Crohns Colitis 2011;5: Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89: Oustamanolakis P, Koutroubakis IE. Soluble transferrin receptorferritin index is the most efficient marker for the diagnosis of iron deficiency anemia in patients with IBD. Inflamm Bowel Dis 2011 Dec;17(12):E Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006;24: de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther 2005;22: Munoz M, Gomez-Ramirez S, Garcia-Erce JA. Intravenous iron in inflammatory bowel disease. World J Gastroenterol 2009;15: Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for irondeficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;34: Crary SE, Hall K, Buchanan GR. Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. Pediatr Blood Cancer 2011;56:615 9.

Managing Anaemia in IBD

Managing Anaemia in IBD Oxford Inflammatory Bowel Disease & Hepatology MasterClass Managing Anaemia in IBD Dr Alex Kent Senior Research Fellow Disclosures WHO Classification of Anaemia Normal haemoglobin and haematocrit levels

More information

Incidence rate of anemia in inflammatory bowel diseases

Incidence rate of anemia in inflammatory bowel diseases Turk J Gastroenterol 2016; 27: 143-8 Incidence rate of anemia in inflammatory bowel diseases BOWEL Özlen Atuğ 1, Haluk Tarık Kani 2, Munkhtsetseg Banzragch 1, Neşe İmeryüz 1, Hakan Akın 1 1 Department

More information

Clinical Course of Infliximab Treatment in Korean Pediatric Ulcerative Colitis Patients: A Single Center Experience

Clinical Course of Infliximab Treatment in Korean Pediatric Ulcerative Colitis Patients: A Single Center Experience pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2014.17.1.31 Pediatric Gastroenterology, Hepatology & Nutrition 2014 March 17(1):31-36 Original Article PGHN Clinical Course of Infliximab

More information

Iron deficiency anaemia in patients with inflammatory bowel disease: National Consultant for Gastroenterology Working Group Recommendations

Iron deficiency anaemia in patients with inflammatory bowel disease: National Consultant for Gastroenterology Working Group Recommendations Special paper Iron deficiency anaemia in patients with inflammatory bowel disease: National Consultant for Gastroenterology Working Group Recommendations Magdalena Kaniewska 1, Witold Bartnik 2,3, Maciej

More information

Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease

Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease Dig Dis Sci (2010) 55:2327 2331 DOI 10.1007/s10620-009-1022-y ORIGINAL ARTICLE Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with

More information

Clinical Study The Effect of Intravenous Iron Treatment on Quality of Life in Inflammatory Bowel Disease Patients with Nonanemic Iron Deficiency

Clinical Study The Effect of Intravenous Iron Treatment on Quality of Life in Inflammatory Bowel Disease Patients with Nonanemic Iron Deficiency Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2015, Article ID 582163, 5 pages http://dx.doi.org/10.1155/2015/582163 Clinical Study The Effect of Intravenous Iron Treatment

More information

Optimizing the effectiveness of anti-tnf therapy in paediatric IBD

Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of

More information

Treatment of Pediatric IBD: What is Different?

Treatment of Pediatric IBD: What is Different? Treatment of Pediatric IBD: What is Different? January 13, 2017 Michael Kappelman MD, MPH University of North Carolina at Chapel Hill Overview Is Pediatric IBD the same disease? Treatment considerations

More information

Martin W Laass 1*, Simon Straub 1, Suki Chainey 2, Garth Virgin 3 and Timothy Cushway 3

Martin W Laass 1*, Simon Straub 1, Suki Chainey 2, Garth Virgin 3 and Timothy Cushway 3 Laass et al. BMC Gastroenterology 214, 14:184 RESEARCH ARTICLE Open Access Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other

More information

Managing peri-operative anaemiathe Papworth way. Dr Andrew A Klein Royal Papworth Hospital Cambridge UK

Managing peri-operative anaemiathe Papworth way. Dr Andrew A Klein Royal Papworth Hospital Cambridge UK Managing peri-operative anaemiathe Papworth way Dr Andrew A Klein Royal Papworth Hospital Cambridge UK Conflicts of interest: Unrestricted educational grants/honoraria from CSL Behring, Brightwake Ltd,

More information

Technologies scoping report

Technologies scoping report Technologies scoping report In response to an enquiry from NHS Greater Glasgow and Clyde Number 18 October 2013 What is the clinical effectiveness, cost effectiveness and implications for safety of assessing

More information

Tariq Iqbal Jürgen Stein Naveen Sharma Stefanie Kulnigg-Dabsch Senthil Vel Christoph Gasche

Tariq Iqbal Jürgen Stein Naveen Sharma Stefanie Kulnigg-Dabsch Senthil Vel Christoph Gasche Dig Dis Sci () 6:7 8 DOI.7/s6--6- ORIGINAL ARTICLE Clinical Significance of C-Reactive Protein Levels in Predicting Responsiveness to Iron Therapy in Patients with Inflammatory Bowel Disease and Iron Deficiency

More information

Managing IBD at the extremes of age: Transitioning Teens

Managing IBD at the extremes of age: Transitioning Teens Oxford Inflammatory Bowel Disease & Hepatology MasterClass Managing IBD at the extremes of age: Transitioning Teens Dr RM Beattie Consultant Paediatric Gastroenterologist Southampton Challenges in the

More information

Medical Therapy for Pediatric IBD: Efficacy and Safety

Medical Therapy for Pediatric IBD: Efficacy and Safety Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission

More information

Positioning Biologics in Ulcerative Colitis

Positioning Biologics in Ulcerative Colitis Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,

More information

Infliximab (Remicade) for paediatric ulcerative colitis - second line

Infliximab (Remicade) for paediatric ulcerative colitis - second line Infliximab (Remicade) for paediatric ulcerative colitis - second line September 2011 This technology summary is based on information available at the time of research and a limited literature search. It

More information

Nutritional Requirements for Inflammatory Bowel Disease. Dale Lee, MD, MSCE Assistant Professor of Pediatrics University of Washington

Nutritional Requirements for Inflammatory Bowel Disease. Dale Lee, MD, MSCE Assistant Professor of Pediatrics University of Washington Nutritional Requirements for Inflammatory Bowel Disease Dale Lee, MD, MSCE Assistant Professor of Pediatrics University of Washington No disclosures Objectives 1) Review the biological mechanisms disturbed

More information

Laboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth

Laboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth Laboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth Why does it matter? Over 30% of the Worlds population are anaemic,

More information

ESPEN Congress Lisbon 2015 NUTRITIONAL ISSUES IN CROHN'S DISEASE. The clash of generations: children are not small adults S.

ESPEN Congress Lisbon 2015 NUTRITIONAL ISSUES IN CROHN'S DISEASE. The clash of generations: children are not small adults S. ESPEN Congress Lisbon 2015 NUTRITIONAL ISSUES IN CROHN'S DISEASE The clash of generations: children are not small adults S. Kolacek (HR) Role of Nutrition in Children with CD Child is NOT a Little Adult

More information

Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: The German AnaemIBD Study

Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: The German AnaemIBD Study Journal of Crohn's and Colitis (2014) 8, 1308 1314 Available online at www.sciencedirect.com ScienceDirect Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency

More information

Hepcidin is a key mediator of anemia of inflammation in Crohn's disease

Hepcidin is a key mediator of anemia of inflammation in Crohn's disease Journal of Crohn's and Colitis (203) 7, e286 e29 Available online at www.sciencedirect.com Hepcidin is a key mediator of anemia of inflammation in Crohn's disease Robert J. Basseri a, Elizabeta Nemeth

More information

EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS

EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS ERIC BENCHIMOL, MD, PhD, FRCPC Associate Professor of Pediatrics and Epidemiology, University of Ottawa Pediatric Gastroenterologist, CHEO

More information

Anaemia in the ICU: Is there an alternative to using blood transfusion?

Anaemia in the ICU: Is there an alternative to using blood transfusion? Anaemia in the ICU: Is there an alternative to using blood transfusion? Tim Walsh Professor of Critical Care, Edinburgh University World Health Organisation grading of the severity of anaemia Grade of

More information

Northern Treatment Advisory Group

Northern Treatment Advisory Group Northern Treatment Advisory Group Ferric Maltol (Feraccru ) for the treatment of iron deficiency Lead author: Daniel Hill Regional Drug & Therapeutics Centre (Newcastle) September 2018 2018 Summary Iron

More information

Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients

Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients Tamás Molnár 1, Klaudia Farkas 1, Tibor Nyári 2, Zoltán Szepes 1, Ferenc Nagy 1,

More information

Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents

Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents Prof. Azza Abdel Shaheed Prof. of Child Health NRC National Research Centre Egypt Prevalence of childhood

More information

YEAR III Pharm.D Dr. V. Chitra

YEAR III Pharm.D Dr. V. Chitra YEAR III Pharm.D Dr. V. Chitra Anemia can be defined as a reduction in the hemoglobin,hematocrit or red cell number. In physiologic terms an anemia is any disorder in which the patient suffers from tissue

More information

Αναιμία και ΙΦΝΕ. Ιωάννης Ε. Κουτρουμπάκης Αναπληρωτής Καθηγητής Γαστρεντερολογίας Ιατρικής Σχολής Πανεπιστημίου Κρήτης

Αναιμία και ΙΦΝΕ. Ιωάννης Ε. Κουτρουμπάκης Αναπληρωτής Καθηγητής Γαστρεντερολογίας Ιατρικής Σχολής Πανεπιστημίου Κρήτης Αναιμία και ΙΦΝΕ Ιωάννης Ε. Κουτρουμπάκης Αναπληρωτής Καθηγητής Γαστρεντερολογίας Ιατρικής Σχολής Πανεπιστημίου Κρήτης 1 Αναιμία και ΙΦΝΕ Ορισμός, αιτιολογία, κλινικά χαρακτηριστικά Επιδημιολογία Παθοφυσιολογικοί

More information

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic

More information

IRON DEFICIENCY / ANAEMIA ANTHONY BEETON

IRON DEFICIENCY / ANAEMIA ANTHONY BEETON IRON DEFICIENCY / ANAEMIA ANTHONY BEETON HYPOXIA 1-2 mg IRON Labile iron Body iron ± 3 4 g Liver and the reticuloendothelial system and spleen (approximately 200 300 mg in adult women and 1 g in adult

More information

Faecal Calprotectin. Reliable Non-Invasive Discrimination Between Inflammatory Bowel Disease (IBD) & Irritable Bowel Syndrome (IBS)

Faecal Calprotectin. Reliable Non-Invasive Discrimination Between Inflammatory Bowel Disease (IBD) & Irritable Bowel Syndrome (IBS) Faecal Calprotectin Reliable Non-Invasive Discrimination Between Inflammatory Bowel Disease (IBD) & Irritable Bowel Syndrome (IBS) Reliable, Non Invasive Identification of IBD vs IBS Available from Eurofins

More information

PEDIATRIC INFLAMMATORY BOWEL DISEASE

PEDIATRIC INFLAMMATORY BOWEL DISEASE PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease

More information

Serum soluble transferrin receptor in hypochromic microcytic anaemia

Serum soluble transferrin receptor in hypochromic microcytic anaemia O r i g i n a l A r t i c l e Singapore Med Med J 2006; J 2006; 47(2) 47(2) : 138 : 1 Serum soluble transferrin receptor in hypochromic microcytic anaemia Jayaranee S, Sthaneshwar P ABSTRACT Introduction:

More information

Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome

Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome Sleep Medicine 6 (2005) 301 305 www.elsevier.com/locate/sleep Original article Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome Christopher J. Earley*, Debbie

More information

Case Discussion. Nutrition in IBD. Rémy Meier MD. Ulcerative colitis. Crohn s disease

Case Discussion. Nutrition in IBD. Rémy Meier MD. Ulcerative colitis. Crohn s disease 26.08.2017 Case Discussion Nutrition in IBD Crohn s disease Ulcerative colitis Rémy Meier MD Case Presentation 30 years old female, with diarrhea for 3 months Shool frequency 3-4 loose stools/day with

More information

Azathioprine for Induction and Maintenance of Remission in Crohn s Disease

Azathioprine for Induction and Maintenance of Remission in Crohn s Disease Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and

More information

Endpoints for Stopping Treatment in UC

Endpoints for Stopping Treatment in UC Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh

More information

The variable risk of colorectal cancer in patients with inflammatory bowel disease.

The variable risk of colorectal cancer in patients with inflammatory bowel disease. The variable risk of colorectal cancer in patients with inflammatory bowel disease. Lindgren, Stefan Published in: European Journal of Internal Medicine DOI: 10.1016/j.ejim.2004.12.001 Published: 2005-01-01

More information

Cows Milk or follow on Formula. Hilton 26/10/2014

Cows Milk or follow on Formula. Hilton 26/10/2014 Iron Deficiency Anemia Cows Milk or follow on Formula Dr Antoine Farah Clinical associate Prof. American University Hospital Hilton 26/10/2014 Iron in infant nutrition: what is the evidence in 2014 IRON

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,

More information

Clinical Study The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency

Clinical Study The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency Hindawi Gastroenterology Research and Practice Volume 2017, Article ID 4585164, 7 pages https://doi.org/10.1155/2017/4585164 Clinical Study The NIMO Scandinavian Study: A Prospective Observational Study

More information

Available Data on Pediatric Exposure Response a Clinician s Perspective

Available Data on Pediatric Exposure Response a Clinician s Perspective Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein

More information

Moderately to severely active ulcerative colitis

Moderately to severely active ulcerative colitis Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients

More information

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014 Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn

More information

Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals

Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker

More information

Genetic Susceptibility. Objectives. What Causes IBD? Inflammatory Bowel Disease

Genetic Susceptibility. Objectives. What Causes IBD? Inflammatory Bowel Disease 4:45 5:30 pm IBD in Pediatrics SPEAKER Jennifer Strople, MD Presenter Disclosure Information The following relationships exist related to this presentation: Jennifer Strople, MD: Speakers Bureau for AbbVie

More information

In Focus - Micronutrients and Obesity: iron deficiency & obesity.

In Focus - Micronutrients and Obesity: iron deficiency & obesity. In Focus - Micronutrients and Obesity: iron deficiency & obesity. Ana Carla Cepeda López MD PhD Universidad de Monterrey, Vicerrectoría de Ciencias de la Salud, Departamento de Ciencias Básicas. Monterrey,

More information

The revised Porto criteria for diagnosing

The revised Porto criteria for diagnosing R E S E A R C H P A P E R Long-term Outcome of Inflammatory Bowel Disease Unclassified in Children SIBA PROSAD PAUL AND BHUPINDER KAUR SANDHU From Bristol Royal Hospital for Children, Upper Maudlin Street,

More information

Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France

Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments

More information

Iron Therapy. Dr Kiran Desai Consultant In Gastroenterology Walsall Manor Hospital

Iron Therapy. Dr Kiran Desai Consultant In Gastroenterology Walsall Manor Hospital Iron Therapy Dr Kiran Desai Consultant In Gastroenterology Walsall Manor Hospital CONFLICTS OF INTEREST Vifor Pharma /Abbvie consultant on their advisory board. Aims 1. Why is it important to understand

More information

Torbjörn Karlsson. Karlsson Journal of Inflammation (2017) 14:21 DOI /s

Torbjörn Karlsson. Karlsson Journal of Inflammation (2017) 14:21 DOI /s Karlsson Journal of Inflammation (2017) 14:21 DOI 10.1186/s12950-017-0166-3 SHORT REPORT Evaluation of a competitive hepcidin ELISA assay in the differential diagnosis of iron deficiency anaemia with concurrent

More information

The National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION

The National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION The National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION You are reading this pamphlet because you or someone you known

More information

Brief Communication: Sensitivity, Specificity, and Predictive Value of Serum Soluble Transferrin Receptor at Different Stages of Iron Deficiency

Brief Communication: Sensitivity, Specificity, and Predictive Value of Serum Soluble Transferrin Receptor at Different Stages of Iron Deficiency Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 35, no. 4, 2005 435 Brief Communication: Sensitivity, Specificity, and Predictive Value of Serum Soluble Transferrin

More information

September 12, 2015 Millie D. Long MD, MPH, FACG

September 12, 2015 Millie D. Long MD, MPH, FACG Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn

More information

Protocol for the management of acute severe ulcerative colitis in children

Protocol for the management of acute severe ulcerative colitis in children Protocol for the management of acute severe ulcerative colitis in children Introduction: Paediatric UC is severe and more extensive than adult onset UC with 6-8% presenting as pancolitis (1,2) Within five

More information

Speaker Introduction

Speaker Introduction Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University

More information

Iron deficiency in heart failure

Iron deficiency in heart failure Iron deficiency in heart failure Piotr Ponikowski, MD, PhD, FESC Department of Heart Diseases, Wroclaw Medical University Centre for Heart Diseases, Military Hospital, Wroclaw, Poland Objectives Importance

More information

Mono or Combination Therapy with. Individualized Approach

Mono or Combination Therapy with. Individualized Approach Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago

More information

Drug Level Monitoring in IBD. Objectives

Drug Level Monitoring in IBD. Objectives Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: fecal_calprotectin_test 8/2009 11/2017 11/2018 11/2017 Description of Procedure or Service Fecal calprotectin

More information

High-dose azathioprine in children with inflammatory bowel disease

High-dose azathioprine in children with inflammatory bowel disease Aliment Pharmacol Ther 2003; 17: 913 921. doi: 10.1046/j.0269-2813.2003.01540.x High-dose azathioprine in children with inflammatory bowel disease D. FUENTES*, F. TORRENTE*, S. KEADY*, K. THIRRUPATHY*,

More information

Clinical Policy: Fecal Calprotectin Assay Reference Number: CP.MP.135

Clinical Policy: Fecal Calprotectin Assay Reference Number: CP.MP.135 Clinical Policy: Reference Number: CP.MP.135 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

DENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease

DENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

Iron depletion in frequently donating whole blood donors. B. Mayer, H. Radtke

Iron depletion in frequently donating whole blood donors. B. Mayer, H. Radtke Iron depletion in frequently donating whole blood donors B. Mayer, H. Radtke Iron: relevance oxygen-transporting and storage proteins hemoglobin and myoglobin iron-containing centers in many enzymes mitochondrial

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant

More information

Short Bowel Syndrome: Medical management

Short Bowel Syndrome: Medical management Short Bowel Syndrome: Medical management La Sindrome dell'intestino Corto in età pediatrica Brescia 18 marzo 2011 Jon A.Vanderhoof, M.D. Division of Pediatric GI Harvard Medical School Children s Hospital,

More information

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment

More information

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center

More information

Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R.

Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R. UvA-DARE (Digital Academic Repository) Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R. Link to publication Citation for published version

More information

Evaluation of treatment effect in UC and CD (children)

Evaluation of treatment effect in UC and CD (children) Evaluation of treatment effect in UC and CD (children) Dr Nick Croft Digestive Diseases, Centre for Immunobiology, Blizard Institute & Barts Health NHS Trust Blizard Institute Disclosures Dr Nick Croft

More information

Impact of endoscopic monitoring in postoperative Crohn s disease patients already receiving pharmacological prevention of recurrence

Impact of endoscopic monitoring in postoperative Crohn s disease patients already receiving pharmacological prevention of recurrence 1130-0108/2015/107/10/586-590 Revista Española de Enfermedades Digestivas Copyright 2015 Arán Ediciones, S. L. Rev Esp Enferm Dig (Madrid Vol. 107, N.º 10, pp. 586-590, 2015 ORIGINAL PAPERS Impact of endoscopic

More information

Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball

Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical

More information

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital Aims To understand the aetiology of IBD To understand the impact that

More information

Update on the management of iron deficiency

Update on the management of iron deficiency Update on the management of iron deficiency Outline Need to improve management & avoid transfusion Diagnosis & investigation Oral iron & IV iron Tools & resources No conflicts of interest All natural

More information

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel

More information

Role of Serum Hepcidin levels in the Diagnosis of Iron Deficiency Anemia in Children in Saudi Arabia

Role of Serum Hepcidin levels in the Diagnosis of Iron Deficiency Anemia in Children in Saudi Arabia Role of Serum Hepcidin levels in the Diagnosis of Iron Deficiency Anemia in Children in Saudi Arabia Mahmoud Mohamed Elgari*, Al-Oufi F¹, Mohammed alsalmi, M. Kurdi, NA Ibrahim, Abdelgadir Elmugadam College

More information

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I

More information

INFLAMMATORY BOWEL DISEASE

INFLAMMATORY BOWEL DISEASE VOLUME 11 NUMBER 4 2011 INFLAMMATORY BOWEL DISEASE Expert commentary on advances in the understanding and management of inflammatory bowel disease MONITOR EditorS-in-Chief Stephen Hanauer Chicago, IL,

More information

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty

More information

Anemia of Inflammation and Chronic Disease

Anemia of Inflammation and Chronic Disease Anemia of Inflammation and Chronic Disease National Hematologic Diseases Information Service U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is anemia? Anemia is a condition

More information

Mucosal healing: does it really matter?

Mucosal healing: does it really matter? Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does

More information

Brief Communication: Association of Serum Insulin-Like Growth Factor-I and Erythropoiesis in Relation to Body Iron Status

Brief Communication: Association of Serum Insulin-Like Growth Factor-I and Erythropoiesis in Relation to Body Iron Status 324 Annals of Clinical & Laboratory Science, vol. 34, no. 3, 2004 Brief Communication: Association of Serum Insulin-Like Growth Factor-I and Erythropoiesis in Relation to Body Iron Status Jong Weon Choi

More information

Long-term outcome after infliximab for refractory ulcerative colitis

Long-term outcome after infliximab for refractory ulcerative colitis Journal of Crohn's and Colitis (2008) 2, 219 225 available at www.sciencedirect.com Long-term outcome after infliximab for refractory ulcerative colitis Marc Ferrante a, Séverine Vermeire a, Herma Fidder

More information

Algorithm for managing severe ulcerative colitis

Algorithm for managing severe ulcerative colitis Tropical Gastroenterology 2014;Suppl:S40 44 Algorithm for managing severe ulcerative colitis Vineet Ahuja 1, Ajay Kumar 2, Rakesh Kochhar 3 ABSTRACT Dept of Gastroenterology, 1 All India Institute of Medical

More information

Hot Topics In Nutrition & IBD January 6, Kate Vance, RD Wael N. Sayej, MD

Hot Topics In Nutrition & IBD January 6, Kate Vance, RD Wael N. Sayej, MD Hot Topics In Nutrition & IBD January 6, 2018 Kate Vance, RD Wael N. Sayej, MD Nutrients of Focus Calories Calcium Vitamin D Iron Nutritional Treatment in IBD Improve nutritional status As primary therapy

More information

Assessing Iron Deficiency in Adults. Chris Theberge. Iron (Fe) deficiency remains as one of the major global public health problems for

Assessing Iron Deficiency in Adults. Chris Theberge. Iron (Fe) deficiency remains as one of the major global public health problems for Assessing Iron Deficiency in Adults Chris Theberge Iron (Fe) deficiency remains as one of the major global public health problems for two reasons. It affects about one fourth of the world s population

More information

children Crohn s disease in MR enterography for GI Complications Microscopy Characterization Primary sclerosing cholangitis Anorectal fistulae

children Crohn s disease in MR enterography for GI Complications Microscopy Characterization Primary sclerosing cholangitis Anorectal fistulae MR enterography for Crohn s disease in children BOAZ KARMAZYN, MD PEDIATRIC RADIOLOGY ASSOCIATE PROFESSOR Characterization Crohn disease Idiopathic chronic transmural IBD Increasing incidence Age 7/100,000

More information

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel

More information

Title: Crohn s disease and cystic fibrosis: there is still a lot to learn

Title: Crohn s disease and cystic fibrosis: there is still a lot to learn Title: Crohn s disease and cystic fibrosis: there is still a lot to learn Authors: Claudio Trigo Salado, Eduardo Leo Carnerero, María Dolores de la Cruz Ramírez DOI: 10.17235/reed.2018.5725/2018 Link:

More information

Genetic and Environmental Risks for IBD

Genetic and Environmental Risks for IBD Genetic and Environmental Risks for IBD CCFA April 26, 2014 Presented by: Name goes here April 30, 2014 TheoTheodore 1 Genetic and Environmental Risks for IBD Theodore M. Bayless, M.D. Director Emeritus

More information

Crohn s disease: scope consultation 19 May June Scope Consultation Table

Crohn s disease: scope consultation 19 May June Scope Consultation Table National Institute for Health and Clinical Excellence Crohn s disease: scope consultation 19 May 2010 16 June 2010 Scope Consultation Table Type Stakeholder Order No Section No Abbott Laboratories 1 3.1

More information

Objectives. Current WHO Definition of Anemia. Implication for Clinical Practice 10/8/18. Prevalence of Iron Deficiency in Women Undergoing Surgery

Objectives. Current WHO Definition of Anemia. Implication for Clinical Practice 10/8/18. Prevalence of Iron Deficiency in Women Undergoing Surgery Pre-operative Anemia Clinic Dr Mike Scott MB ChB FRCP FRCA FFICM Professor in Anesthesiology and Critical Care Medicine Divisional Lead for Critical Care Medicine VCU Health System, Richmond, VA Professor

More information

Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG

Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.

More information

FOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015

FOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015 Contact: Ross Selby Takeda UK Ltd Email ross.selby@takeda.com News Release FOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015 World s first gut-selective treatment for ulcerative colitis

More information

Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort

Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division

More information

NZBS HAEMOCHROMATOSIS & THERAPEUTIC VENESECTION POLICY

NZBS HAEMOCHROMATOSIS & THERAPEUTIC VENESECTION POLICY REASON FOR ISSUE: New Document for TV Clinic 1. INTRODUCTION NZBS will provide a venesection service for people in New Zealand who require venesection for conditions that are known to benefit from therapeutic

More information

Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center

Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center CROHN S DISEASE Patchy inflammation Mouth to anus involvement Full-thickness inflammation Variable involvement

More information

Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-ibd gastroenterologists

Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-ibd gastroenterologists ORIGINAL ARTICLE Annals of Gastroenterology (2017) 30, 1-5 Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-ibd gastroenterologists Mohammad

More information